. ER is raised in puberty and pregnancy but never to levels reached in carcinoma (Israel & Band, 1984) . Even in ER positive breast cancer there is no significant binding in the histologically normal surrounding tissue (Johansson et al., 1970) . Indeed Israel and Band (1984) developed the hypothesis that the presence of ER in malignant disease is a direct consequence of neoplastic transformation and oncogene expression. This hypothesis has recently received considerable support from the characterisation of oestrogen receptor cDNA, which shows structural similarities to known oncogenes (Green et al., 1986) . To our knowledge, a systematic comparison between the receptor content of a tumour and the whole of the remainder of the breast has not been reported. Therefore this paper reports the results obtained from such an analysis of nine mastectomy specimens with ER positive tumours.
The significance of the presence of oestrogen and progesterone receptors (ER & PR) in breast tumours has been emphasized by many authors because of its implications for the progression of the disease and its management (Hubay et al., 1984; Seibert & Lippman, 1982) . It is less clear how the expression of receptors in tumour relates to the incidence in normal tissue. Some studies suggest that receptor content is greatest in malignant and proliferative benign breast disease (Allegra et al., 1979; Jacquemier et al., 1982) whereas in normal breast tissue ER is virtually undetectable (Jacquemier et al., 1982; Terenius et al., 1974) . ER is raised in puberty and pregnancy but never to levels reached in carcinoma (Israel & Band, 1984) . Even in ER positive breast cancer there is no significant binding in the histologically normal surrounding tissue (Johansson et al., 1970) . Indeed Israel and Band (1984) developed the hypothesis that the presence of ER in malignant disease is a direct consequence of neoplastic transformation and oncogene expression. This hypothesis has recently received considerable support from the characterisation of oestrogen receptor cDNA, which shows structural similarities to known oncogenes (Green et al., 1986) . To our knowledge, a systematic comparison between the receptor content of a tumour and the whole of the remainder of the breast has not been reported. Therefore this paper reports the results obtained from such an analysis of nine mastectomy specimens with ER positive tumours.
Materials and methods

Patients
In all cases a preoperative attempt was made to confirm the presence of malignancy either by aspiration cytology or by Trucut biopsy. Where malignancy was not confirmed, excision biopsies were performed for frozen section at the time of mastectomy. Ischaemic time, which might affect receptor values (Leight et al., 1984; Teichner et al., 1985) , was minimal in the operative procedure used. The breast was left attached to the axillary structures until fully mobilised, when it was removed between clamps and only following sampling for receptor analysis and histology was the required axillary procedure carried out. The removed breast was divided into 16 equal sectors ( Figure 1 ) and specimens at least 1 cm3 in size were removed from the centre of each sector. Grossly visible fat having been removed, the tissues were divided into two equal halves and used respectively for receptor assay and histological examination.
Specimens were collected from the posterior aspect of the breast and always from medial to lateral and cranio-caudally (i.e. Al, A2,... D4, cf. Figure 1) (200 p1 of 0.25% charcoal 0.025% dextran in 10mM Tris 1.5mm EDTA buffer, pH 7.4) was added to each tube, mixed and incubated for 10 min. After centrifugation (5 min at 10,000g) portions of supernatant (200,l) were added to 8 ml liquid scintillation cocktail (4 g PPO, 0.05 g POPOP in toluene). Steroid was extracted into the organic phase by vigorous shaking, and radioactivity measured in a Beckman LS7500 liquid scintillation spectrometer with correction for quenching in order to obtain dpm. Counts from the tubes containing competitor (non-specific binding) were subtracted from those of tubes without competitor (total binding) to give values for hormone specifically bound to receptor. Receptor concentration was calculated from these values by using the specific activity of the titrated steroid, and expressed as fmol mg-I protein. Values were means of duplicate estimations. For PR, similar methods were employed, with 3H-progesterone (100 nM) as the labelled ligand, and norethindrone (100 fold excess) as the unlabelled competitor. In PR analysis, cortisol (100 fold excess) was also added to displace the labelled ligand from transcortin. Protein estimations (Lowry et al., 1951) were carried out with bovine serum albumin as the standard.
Validation of the single saturating dose receptor assay The single saturating dose (SSD) receptor assay has been validated in several ways: (i) sequential estimations of ER in a control uterine cytosol preparation gave an interassay coefficient of variation (COV) of 17% (n=34); (ii) the intraassay COV was 6% (n = 6); (iii) comparison between the SSD and the Scatchard methods of ER measurement gives an excellent correlation (r = 0.97; n = 50; P <0.001; Puddefoot et al., 1986) ; (iv) sequential assay of PR in uterine cytosol preparations gave an interassay COV of 12.5% (n = 33). Shortage of suitable material and variable non-specific binding precluded comparison between the SSD and Scatchard methods in this case. However, quality control exercises in which tumours were also assayed by another laboratory gave good agreement between laboratories (Puddefoot et al., 1986) . Histopathology Samples were fixed in buffered formalin and processed to paraffin in the usual way. Sections of 5 gm were examined in haematoxylin and eosin preparations.
Results
Data from 9 patients whose primary tumours were ER positive were obtained. Of these, two were premenopausal (cases 2 and 17, aged 38 and 49), one perimenopausal (case 6, aged 53), and the remaining six were postmenopausal subjects aged 46-75. Oestrogen receptor data and histological findings are illustrated in Figure 2 . In all cases, the ER content was much higher in the ER positive tumours than in the nonmalignant specimens (see Table I ). In one case (17) Seibert & Lippman, 1982) . There may be several reasons why this should be. Most importantly, it is clear that the disease, as judged by hormone receptor content, takes several forms. Most obvious is the well documented recognition of at least four phenotypes for soluble (previously termed 'cytoplasmic', Walters, 1985) receptor status, i.e., ER positive/PR positive, ER positive/PR negative, ER negative/PR positive, ER negative/PR negative. Additional variants are recognised when nuclear-bound receptors are also considered. Further evidence for heterogeneity also emerges when receptor affinities are taken into account (Puddefoot et al., 1986) . Moreover, data accumulated in the last few years has shown quite clearly that such heterogeneity is even to be found in the tumour tissue of individual patients. For receptor contents (Tilley et al., 1978; Braunsberg, 1975; Silfersward et al., 1980; van Netten et al., 1985) . Recently, too, the development of monoclonal antibodies to receptors has made possible the application of immunohistochemical techniques which in some cases show adjacent ER positive and ER negative tumour cells (King et al., 1985) . The present results confirm and extend these findings. One striking observation is that patients show extraordinary diversity in the nature of their disease. Not only do nearly all show benign breast disease as well as cancer (Figures 2,  3 Table I ). The same relationship is not unerringly found for PR. In some cases PR content of PR positive tumours is higher than in the other tissue (e.g. cases 1 and 2, see Figure 3 ) although comparison with Figure 2 shows the effect is not so marked as for ER. In other cases (e.g. 10 and 17) highest PR values are found in non-tumour tissue. There would appear to be no relationship between ER status and tumour differentiation (Table I) , although it is possible that poorly differentiated tumours have low PR content.
It is obviously difficult to be sure that the material divided between histopathologist and biochemist is always quite homogeneous. In this connection some samples of relatively high receptor content were found in fat or connective tissue, (e.g. cases 1, 10, Figure 2 ). Here it may be suspected that the samples were not identical, and those taken for receptor analysis may have contained tumour cells in addition to normal tissue.
With this caveat in mind, however, it is nevertheless clear that the data supports the hypothesis that ER concentration in ER positive tumours reflects the transformed function of neoplastic tissue (Israel & Band, 1984) . Following other work (Green et al., 1986) , it also suggests that the expression of the oncogene involved may be related to ER functions.
